Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
Rhea-AI Summary
Ludwig Enterprises (OTC PINK:LUDG) has filed a provisional patent for a novel cancer detection method called 'mRNAs Differentially Expressed in Cancer.' The breakthrough technology uses a six-mRNA gene combination that shows enhanced sensitivity and specificity in breast cancer detection. The development is based on research involving over 3,300 cheek cell samples from 40 U.S. medical centers, where AI analyzed more than 12 million combinations of a 48-gene mRNA microarray. The company plans to rebrand as Revealia™ in 2024, subject to regulatory approvals.
Positive
- Filed provisional patent for new cancer detection method
- Demonstrated improved sensitivity and specificity in breast cancer detection
- Extensive research base with 3,300+ patient samples from 40 medical centers
Negative
- Pending regulatory approvals required for company rebranding
- Early-stage technology without proven commercial success
News Market Reaction
On the day this news was published, LUDG declined 4.55%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled "mRNAs Differentially Expressed in Cancer." The company's latest innovation, which analyzes a six-mRNA gene combination, has demonstrated a significant increase in sensitivity and specificity for breast cancer detection, compared to previous methods. "We were already doing well, but this is an incredible performance the likes of which we haven't seen in the genetic breast cancer screening test market," stated Marvin S. Hausman MD, CSO. Our innovative and non-invasive screening test empowers people to be proactive with their medical care, and potentially detect health issues early on."
This advancement emerges from extensive research involving over 3,300 cheek cell samples collected from patients across 40 U.S. medical centers, where proprietary machine learning AI technology analyzed more than 12 million combinations of the company's 48-gene mRNA microarray.
In conjunction with this breakthrough, the company announced plans to rename itself as Revealia™, Inc., pending regulatory approvals and a corresponding ticker symbol change.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than
For more information please visit: http://www.ludwigent.com. www.revealia.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: LUDG_inc
Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com
SOURCE: Ludwig Enterprise, Inc.
View the original press release on accesswire.com
FAQ
What is Ludwig Enterprises' new cancer detection patent about?
How many patient samples were used in Ludwig Enterprises' cancer detection research?
When will Ludwig Enterprises change its name to Revealia?
